Evogene Ltd (NASDAQ:EVGN) has earned a consensus broker rating score of 2.00 (Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. One analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.
Brokers have set a twelve-month consensus target price of $14.00 for the company and are predicting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also given Evogene an industry rank of 73 out of 265 based on the ratings given to its competitors.
Evogene (NASDAQ:EVGN) opened at 8.05 on Monday. The company has a 50 day moving average price of $6.95 and a 200-day moving average price of $8.17. Evogene has a one year low of $6.26 and a one year high of $10.54. The firm’s market capitalization is $204.42 million.
Evogene (NASDAQ:EVGN) last announced its earnings results on Wednesday, November 18th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.02. The business earned $3.31 million during the quarter, compared to analyst estimates of $3.50 million. On average, equities analysts predict that Evogene will post ($0.89) EPS for the current year.
Several research analysts have recently commented on the company. Piper Jaffray reduced their target price on Evogene from $12.00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, November 19th. Zacks Investment Research raised Evogene from a “sell” rating to a “hold” rating in a report on Friday, October 16th.
Evogene Ltd. is a plant genomics company. The Company uses an integrated technology infrastructure to enhance seed traits underlying crop performance and productivity through biotechnology and advanced breeding methods. Using its cutting edge computational genomics technologies, ATHLETE, Gene2Product and EvoBreed, the Company specializes in improving traits through applying biotechnology and advanced breeding for a variety of crops. The Company has collaborations with agricultural companies, primarily to develop traits for improved yield and abiotic stress tolerance, such as improved tolerance to drought, heat and salinity and biotic stress resistance, such as resistance to disease, pests and insects), focusing on essential crops, including corn, soybean, wheat, rice and cotton.
For more information about research offerings from Zacks Investment Research, visit Zacks.com